Delta-2-tubulin as a biomarker and therapeutic target for peripheral neuropathy
AssigneesThe Trustees of Columbia University in the City of New York, Universita Degli Studi Di Milano-Bicocca
InventorsFrancesca Bartolini, Maria Elena Pero, Guido Cavaletti
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to delta-2-tubulin and its use as a biomarker for determining if a subject is at risk of developing peripheral neuropathy or if a subject has developed peripheral neuropathy. The present disclosure further relates to methods for the treatment of peripheral neuropathy in a subject and assays for identifying compounds that can be used to treat and/or prevent peripheral neuropathy.
Claims9
A method for the treatment of chemotherapy-induced peripheral neuropathy in a subject having cancer, the method comprising:
- determining an increased level of delta-2-tubulin in a sample of nervous tissue obtained from the subject, and
- administering an effective amount of an siRNA or shRNA targeting cytosolic carboxypeptidase 1 (CCP1), cytosolic carboxypeptidase 4 (CCP4), or cytosolic carboxypeptidase 6 (CCP6) or a pharmaceutical composition thereof.
Dependencies are inferred from the claim text.